Additional file 1 of Ultrasmall PtMn nanoparticles as sensitive manganese release modulator for specificity cancer theranostics
Creators: name: Guan, Guoqiang
name: Liu, Huiyi
name: Xu, Juntao
name: Zhang, Qingpeng
name: Dong, Zhe
name: Lei, Lingling
name: Zhang, Cheng
name: Yue, Renye
name: Gao, Hongchang
name: Song, Guosheng
name: Shen, Xian
Publisher: name: figshare
Year: 2023
Subjects: subject: Biophysics
subject: Biochemistry
subject: Space Science
subject: Cell Biology
subject: Pharmacology
subject: Biotechnology
subject: Chemical Sciences not elsewhere classified
subject: Cancer
subject: Inorganic Chemistry
subject: FOS: Chemical sciences

description: Additional file 1: Table S1. The detailed peak positions for the fitted Pt peaks. Table S2. The detailed peak positions for the fitted Mn peaks. Table S3. The summary of added precursor ratios and obtained element percent for various PtMn nanoparticles was determined from ICP. Fig. S1 (a) XPS spectra of Mn 2p for PtMn-1 after incubation in HEPES (10x, 5.4) at room temperature for 1 h. (b) The percentage of Mn2+ or Mn3+ within PtMn-1 before and after incubation in acidic conditions (pH 5.4), determined from XPS in Figure 1k and Figure S1a. Fig. S2 1H NMR of non-responsive polymer. Fig. S3 1H NMR of pH-responsive polymer. Fig. S4 MALDI-TOF of pH-responsive polymer. Fig. S5 GPC tests of pH-responsive polymer. Fig. S6 Absorption spectra of TMBox incubated with R-PtMn-1 (a), R-PtMn-2 (b) or R-PtMn-3 (c) in HEPES buffer at different pH (pH= 7.4, 6.8, 6.4, 6.0, or 5.4). Fig. S7 Absorption spectra of TMBox incubated with Nr-PtMn-1 in different pH values. Fig. S8 Hydrodynamic size of R-PtMn-1 dispersed in H2O, DPBS, HEPES, or DMEM for different times. Fig. S9 Hydrodynamic size of R-PtMn-2 or R-PtMn-3 dispersed in H2O, DPBS, HEPES, or DMEM for 12 h. Fig. S10 Hydrodynamic size of R-PtMn-1 dispersed in HEPES buffer with different pH values for 12 h. Fig. S11 The percentage of GSH-consumed for Nr-PtMn-1 in different pH at 12 h. Fig. S12 (a) Quantitative analysis of relative GPX4 levels. (b) Quantitative analysis of relative BID levels. (c) Quantitative analysis of relative ASCL4 levels. Fig. S13 The relative cellular viability of 4T1 cancer cells treated with various concentrations of R-PtMn-2 (a) or R-PtMn-3 (b) for 24 h. Fig. S14 The relative cellular viability of CT26 cancer cells treated with various concentrations of R-PtMn-2 (a) or R-PtMn-3 (b) for 24 h. Fig. S15 Confocal images of DCHF-DA-stained HEK293 normal cells pre-treated R-PtMn-1. Fig. S16 Confocal images of liperfluo-stained HEK293 normal cells pre-treated R-PtMn-1. Fig. S17 The relative cellular viability of HEK293 normal cells treated with various concentrations of R-PtMn-1 for 24 h. Fig. S18 Body weights of mice bearing CT26 tumor from each group post various treatments were recorded every other day during 14 days study. Fig. S19 Body weights of mice bearing 4T1 tumor from each group post various treatments were recorded every other day during 14 days’ of study. Fig. S20 H&amp;E-stained images of major organs in CT26 tumors bearing mice from one of each group. Those organs were collected on the 14th day post various injections. Fig. S21 H&amp;E-stained images of major organs in 4T1 tumors bearing mice from each group. Those organs were collected on the 14th day post various injections.